This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Bloodwise | |
|---|---|
| Name | Bloodwise |
| Founded | 1960 |
| Founder | Anthony Nolan (see also Anthony Nolan for context) |
| Type | Charity |
| Headquarters | London, United Kingdom |
| Area served | United Kingdom |
| Focus | Leukaemia, lymphoma, myeloma, blood disorders |
Bloodwise is a United Kingdom-based charity dedicated to funding research, supporting patients, and campaigning for people affected by leukaemia, lymphoma, myeloma and related blood disorders. Founded in the mid-20th century, the charity operates across healthcare, scientific research and public policy spheres, interacting with hospitals, universities, regulators and patient groups. It has been a major funder of translational research and has engaged in national advocacy, awareness and fundraising initiatives.
The organization traces roots to postwar clinical efforts and patient advocacy emerging alongside institutions such as St Thomas' Hospital, Great Ormond Street Hospital, Royal Marsden Hospital and research centres at University of Oxford and University of Cambridge. Early collaborations involved clinicians from National Health Service hospitals, researchers at the Medical Research Council and patient advocates associated with groups like Macmillan Cancer Support and Marie Curie; founders and trustees drew on networks that included figures connected to NHS Blood and Transplant and the blood donation movement exemplified by British Red Cross. Over decades, the charity expanded governance and merged or coordinated with other entities in the haemato-oncology space, aligning with European partners such as European Hematology Association and international registries like Bone Marrow Donors Worldwide.
The charity’s mission centers on funding science to improve diagnosis, treatment and care for people with blood cancers and blood disorders, while supporting families and influencing health policy. Its activities span translational research partnerships with institutions including Imperial College London, King's College London, University College London, University of Manchester and clinical networks such as NHS Blood and Transplant and regional cancer alliances. Public engagement efforts have involved campaigns tied to national awareness days, collaborations with media outlets like BBC and fundraising events inspired by models used by Red Nose Day and Sport Relief. Volunteer and community mobilisation reflects civic organisations such as Royal Voluntary Service and patient advocacy movements connected to Sense About Science.
Research funding priorities include basic biology, genomics, clinical trials and survivorship studies undertaken at centres like The Francis Crick Institute, Wellcome Sanger Institute, Cancer Research UK-affiliated units and specialist haematology departments at Royal Free Hospital and Addenbrooke's Hospital. Grants have supported work on targeted therapies, immunotherapies related to CAR-T development, and studies referencing frameworks from National Institute for Health and Care Excellence guidance. The charity has partnered with funders such as Wellcome Trust, Medical Research Council and industry partners including multinational pharmaceutical firms headquartered in Basel and New Jersey. It has administered fellowships, pilot grants and program awards that connect early-career researchers to clinical trial networks like UK Clinical Trials Gateway and regulatory bodies such as Medicines and Healthcare products Regulatory Agency.
Support services include information provision, helplines, peer support networks and practical assistance coordinated with hospital social work teams at Royal London Hospital, Guy's and St Thomas' NHS Foundation Trust and regional cancer centres. Psycho-oncology collaborations draw on expertise at Institute of Psychiatry, Psychology and Neuroscience and survivorship programs mirror initiatives at Macmillan Cancer Support and Marie Curie. The charity has produced patient-facing materials informed by clinical guidelines produced by groups such as British Society for Haematology and NICE, and has facilitated access to clinical trials run through networks like Cancer Research UK and regional research hubs at Manchester Cancer Research Centre.
Advocacy efforts have targeted national policy debates involving Department of Health and Social Care, parliamentary committees including the Health and Social Care Select Committee, and regulatory frameworks shaped by NICE and Medicines and Healthcare products Regulatory Agency. Major campaigns have sought to increase diagnosis rates, improve access to novel therapies and address workforce issues in haematology linked to professional bodies such as Royal College of Physicians and Royal College of Pathologists. Public awareness work has used media partnerships with outlets like the BBC and national fundraising models comparable to Comic Relief and Children in Need.
The charity is governed by a board of trustees and executive officers who liaise with clinical advisory panels and research steering committees composed of academics from institutions like University of Edinburgh, University of Glasgow, Cardiff University and University of Birmingham. Financial oversight interfaces with auditors and regulators including Charity Commission for England and Wales and reporting standards aligned to bodies like Institute of Chartered Accountants in England and Wales. Governance practices include patient and public involvement modeled on frameworks used by INVOLVE and advisory inputs from clinicians affiliated to specialist centres such as University Hospitals Birmingham.
Strategic partnerships span universities, NHS trusts, international research consortia and patient groups, including collaborations with European Hematology Association, Bone Marrow Donors Worldwide and trial consortia linked to Cancer Research UK. Impact metrics cite funded publications from teams at Wellcome Sanger Institute, translational benefits realized in haematology services at Addenbrooke's Hospital and changes in clinical pathways influenced through policy engagement with Department of Health and Social Care and professional bodies like the British Society for Haematology. The charity’s work continues to intersect with global science hubs such as Harvard Medical School, Massachusetts General Hospital, Johns Hopkins Hospital and European centres in Paris, Berlin and Amsterdam.